Comparative Pharmacology
Head-to-head clinical analysis: DURANEST versus LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURANEST versus LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER.
DURANEST vs LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonidate is an ultrashort-acting nonbarbiturate hypnotic agent that produces anesthesia by enhancing GABA-mediated chloride conductance at GABA-A receptors, leading to central nervous system depression.
Blocks voltage-gated sodium channels, inhibiting action potential propagation in neurons and cardiac myocytes.
2-10 mL of a 1-2% solution, subarachnoid injection, single dose only.
1-1.5 mg/kg IV bolus, then 0.5-0.75 mg/kg IV bolus every 5-10 min to a max of 3 mg/kg total loading dose; maintenance infusion 1-4 mg/min IV. For epidural: 5-10 mL of 1-2% solution.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours (range 3-6 hours). Clinical context: Prolonged in severe hepatic impairment but not significantly in renal impairment.
Terminal elimination half-life: 1.5–2 hours (single dose); prolonged to 2–3 hours with repeated dosing or in heart failure, liver disease, or elderly. Context: Effective for 1–2 hours after IV bolus, requiring infusion for sustained effect.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug. Biliary/fecal elimination is minimal.
Renal excretion of unchanged drug and metabolites: ~90% as metabolites (e.g., monoethylglycinexylidide, glycinexylidide), <10% unchanged. Biliary/fecal: minimal (<1%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)